C4 Therapeutics Inc.
CCCC | NASDAQ
$3.30
-$0.09 (-2.65%)
At close: Sep 21, 2026, 4:00 PM ET
$3.30
$0 (0.00%)
Pre-market:
Sep 22, 2026, 4:00 AM ET
Market Data
Market Cap $374.82M
Enterprise Value $168.07M
Beta 2.95
Average Volume 2.97M
Shares Outstanding (Diluted) 130.7M
Shares Change YoY 84.07%
Institutional Ownership 67.02%
Exchange NASDAQ
ISIN US12529R1077
Price Performance
Price Change 1M -16.9%
Price Change 3M -21.8%
Price Change 6M 22.7%
Price Change YTD 71.0%
Price Change 1Y 26.4%
Price Change 3Y 61.8%
Price Change 5Y -93.3%
1M CAGR (ann.) -6.9%
1Y CAGR (ann.) 0.3%
5Y CAGR (ann.) -41.4%
All-Time CAGR -28.7%
Valuation
PE Ratio -3.30
Forward PE N/A
PEG Ratio -0.07
Forward PEG -0.31
PS Ratio 10.41
Forward PS 17.80
PB Ratio 1.48
P/FCF Ratio -4.27
P/Adj. FCF Ratio -3.66
P/OCF Ratio -5.08
EV/Sales 4.80
EV/EBIT -1.66
EV/EBITDA -1.71
EV/FCF -1.97
Earnings Yield -30.3%
FCF Yield -23.4%
Adj. FCF Yield -27.3%
Financial Health
Net Cash $253.66M
Total Debt $56.86M
Cash & Short-Term Investments $253.66M
Total Assets $359.4M
Current Ratio 5.45
Quick Ratio 5.45
Debt / Equity Ratio 0.23
Debt / EBITDA -0.58
Debt / FCF -0.67
OCF / Debt -1.49
Interest Coverage 0.00
Altman Z-Score -1.18
Piotroski F-Score 4
Margins & Profitability
Gross Profit Margin 94.9%
Operating Profit Margin -319.0%
EBITDA Margin -280.6%
Net Profit Margin -289.4%
FCF Margin -243.7%
Adj. FCF Margin -284.5%
SBC / Revenue 40.8%
SBC Impact (per share) -16.8%
Returns
Return on Assets -28.2%
Return on Equity -45.5%
Return on Invested Capital -35.2%
Return on Capital Employed -35.9%
Return on Tangible Assets -28.2%
Historical Growth (CAGR)
Revenue CAGR 3Y 29.8%
Revenue CAGR 5Y 0.7%
Revenue CAGR 10Y N/A
EPS CAGR 3Y 30.1%
EPS CAGR 5Y 17.7%
EPS CAGR 10Y N/A
FCF CAGR 3Y -4.0%
FCF CAGR 5Y 4.8%
FCF CAGR 10Y N/A
Analyst Forecasts
Analyst Rating Buy
Analyst Count 14
EPS Growth Next 3Y 57.7%
Revenue Growth Next 3Y 181.0%
Earnings Date N/A
EPS Estimate (next Q) N/A
EPS Growth Est (next Q) N/A
Revenue Est (next Q) N/A
Revenue Growth Est (next Q) N/A
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $11.33
Price Target Upside 243.3%
Cash Flow
Operating Cash Flow $-84.87M
Free Cash Flow $-85.39M
Adj. Free Cash Flow $-99.7M
FCF Per Share -$0.65
OCF Per Share -$0.65
OCF/S Ratio -242.2%
Income Statement
Revenue $35.04M
Gross Profit $33.24M
Operating Income $-111.77M
EBITDA $-98.31M
Net Income $-101.42M
EPS (Diluted) -$1
Revenue / Employee $336.91K
Profit / Employee $-975.15K
Employees 104
Add to Watchlist
Select watchlists to add or remove CCCC